They demonstrated that anti-BCMA rCAR-T therapy was safe and able to meaningfully decrease MG severity scales (i.e. MG-ADL, MGC, QMG, and MG-QoL-15r scores) at up to 9 months of follow-up (71). The gene discussed is TNFRSF17; the disease is myasthenia gravis.